Patents Issued in September 8, 2020
  • Patent number: 10765627
    Abstract: The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-C. jejuni immune response.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 8, 2020
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Mario Artur Monteiro
  • Patent number: 10765628
    Abstract: The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: September 8, 2020
    Assignee: The Population Council, Inc.
    Inventors: George William Creasy, II, Ruth Beverly Merkatz
  • Patent number: 10765629
    Abstract: Described herein is a solid complex comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter “Compound 1”) and ?-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: September 8, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ke Wu, Evgenyi Shalaev, Prem Swaroop Mohanty, Jinping Wan
  • Patent number: 10765630
    Abstract: The present invention is a method of treating enteropathic arthritis in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), and/or a salt thereof; and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: September 8, 2020
    Assignee: SEN-JAM PHARMACEUTICAL LLC
    Inventors: Jacqueline Iversen, Thomas A. Dahl
  • Patent number: 10765631
    Abstract: Embodiments of the invention relate to liposomes comprising: a lipid bilayer having an internal cavity; a therapeutic agent within the internal cavity configured to modify expression or degradation of WASp in a cell; and a targeting moiety external to the lipid bilayer configured to target an extracellular domain of a cell. Embodiments of the invention relate to methods of treatment of disease comprising administering the liposomes. Novel pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 8, 2020
    Assignee: BAR-ILAN UNIVERSITY
    Inventor: Mira Barda-Saad
  • Patent number: 10765632
    Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest effectiveness in therapy, prophylaxis or diagnosis. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 8, 2020
    Assignee: CURADIGM SAS
    Inventors: Matthieu Germain, Marie-Edith Meyre, Agnes Pottier, Laurent Levy
  • Patent number: 10765633
    Abstract: A formulation comprising liposomes, wherein the liposomes comprise, based on the liposome, 0.7 to 3.0 mol % of eritoran or a pharmaceutically acceptable salt thereof and 0.5 to 3.0 mol % of a PEGylated phospholipid.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: September 8, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD
    Inventors: Hiroshi Ishihara, Katsura Hata, Hiroki Muto, Geoff Hird
  • Patent number: 10765634
    Abstract: The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-?, and/or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: September 8, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Steven R. Little, Giorgio Raimondi, Angus W. Thomson, Siddharth Jhunjhunwala
  • Patent number: 10765635
    Abstract: Various embodiments of modified-release multiparticulates (in bead or granule from) are described. The modified-release multiparticulates can comprise a core including a pharmaceutical and/or probiotic agent, optionally with additional excipients or binders to aid in creation of the core, one or more functional coatings disposed on the core and configured to provide a modified-release profile of the pharmaceutical and/or probiotic agent when given orally, and a coating of hypromellose acetate succinate (HPMCAS) disposed on the one or more functional coatings and configured to impart multiparticulate stability in aqueous acidic media. Suspensions including the modified-release multiparticulates are also described.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: September 8, 2020
    Inventors: Robert Niichel, Samuel Reinhold, III, Clayton J. Nelsen, Dan A. Finkbeiner, Roy J. McDaniel, Andrew D. Padilla
  • Patent number: 10765636
    Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Andre E. Nel, Huan Meng, Xiangsheng Liu
  • Patent number: 10765637
    Abstract: Provided is a composition which can be utilized for drug delivery systems that can penetrate the blood brain barrier, and has low cytotoxicity. A nanoparticle composition comprises nanoparticles to the surface of which a first substance and a second substance each having specificity to a tumor cell are bound, wherein the first substance having specificity to the tumor cell is a peptide comprising an amino acid sequence of arginine-glycine-aspartic acid, and wherein the second substance having specificity to the tumor cell is an iron-binding protein, and wherein the nanoparticles each comprise an outer layer and vesicles enveloped by the outer layer and the nanoparticles each comprise, as membrane components, a PEGylated phospholipid, a fatty acid with a melting point of 30° C. or more, and a non-PEGylated phospholipid.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: September 8, 2020
    Assignee: TOYO UNIVERSITY
    Inventors: Toru Maekawa, Sakthikumar Dasappan Nair, Sheikh Mohamed Mohamed, Srivani Veeranarayanan
  • Patent number: 10765638
    Abstract: Compositions and methods for efficient delivery of therapeutic agents in vivo are provided. Typically, the compositions are in the form of polymeric particles formed from one or more therapeutic agent complexed with a polycationic polymer which is further encapsulated in one or more amphiphilic polymers, preferably diblock copolymer of a polyalkylene oxide and a polyester such as poly(D,L-lactide)-poly(ethylene glycol) (PLA-PEG). In the preferred embodiments, the chemotherapeutic agent reduces, or inhibits N-glycosylation of one or more receptor tyrosine kinases of cancer cells. Methods of using the particles to treat cancer are also provided.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 8, 2020
    Assignee: YALE UNIVERSITY
    Inventors: W. Mark Saltzman, Joseph Contessa, Amanda King
  • Patent number: 10765639
    Abstract: The invention concerns nanocapsules in the form of a colloidal suspension or in dry form, said nanocapsules comprising at least an active ingredient in the form of an oil, one ionic surfactant, optionally one nonionic surfactant, and one hydrophilic polymer. The invention also concerns their manufacture and their uses.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: September 8, 2020
    Assignee: ADISSEO FRANCE S.A.S.
    Inventors: Damien Preveraud, Véronique Rosilio
  • Patent number: 10765640
    Abstract: [Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2,000 g/50 mm and of biaxially-oriented stretch cloth.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: September 8, 2020
    Assignees: ITOCHU CHEMICAL FRONTIER Corporation, OISHI KOSEIDO CO., LTD.
    Inventors: Tatsuya Mori, Naoyuki Saida
  • Patent number: 10765641
    Abstract: The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology to combat redness. More specifically, the present invention relates to the cosmetic use of a composition comprising said combination to combat rosacea.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 8, 2020
    Assignee: PIERRE FABRE DERMOT-COSMETIQUE
    Inventors: Hélène Hernandez-Pigeon, Nathalie Castex-Rizzi, Stéphane Poigny, Marie Françoise Aries, Yves Brunel
  • Patent number: 10765642
    Abstract: The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 8, 2020
    Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Ki Sun Kwon, Jeongi Choi, Sung Sup Park, Sun Gun Chung, Eun Soo Kwon, Kwang-Pyo Lee, Seung Min Lee
  • Patent number: 10765643
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 8, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10765644
    Abstract: The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: September 8, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi
  • Patent number: 10765645
    Abstract: This application describes a compound represented by Formula (I): YZX1—S(O)(X2)F)m]n??(I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 8, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jiajia Dong, K. Barry Sharpless, Jeffery W. Kelly, Aleksandra Baranczak, Wentao Chen
  • Patent number: 10765646
    Abstract: Methods of treating developmental encephalopathies by administering compositions including ketamine, norketamine, or other derivatives of ketamine, or a pharmaceutically acceptable salt of any of the foregoing, are provided. The methods and compositions may be used to treat conditions such as Dravet syndrome.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 8, 2020
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10765647
    Abstract: Provided is a composition for treating diabetes, including a hypoglycemic agent and a Yukmijihwang-tang extract. More particularly, the hypoglycemic agent is administered into an individual, and the Yukmijihwang-tang extract is administered into the individual, thereby considerably increasing a hypoglycemic effect of the hypoglycemic agent, and preventing and reducing various diabetic complications such as diabetes and diabetic liver damage, renal damage, hyperlipidemia immunosuppression and ocular damage.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 8, 2020
    Assignee: COMPREHENSIVE AND INTEGRATIVE MEDICINE INSTITUTE
    Inventors: Seok Bong Kang, Ho Sang Sohn, Joon Seok Byun, Ki Cheul Sohn, Sae Kwang Ku
  • Patent number: 10765648
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 8, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • Patent number: 10765649
    Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: September 8, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Drazen Ostovic, Gary Fred Musso
  • Patent number: 10765650
    Abstract: A composition for mixing with water for use as an oral rinse, comprising monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, calcium chloride, and an analgesic/anaesthetic such as benzocaine/lidocaine.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 8, 2020
    Assignee: Forward Science Technologies, LLC
    Inventors: Brian Pikkula, Robert J. Whitman
  • Patent number: 10765651
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 8, 2020
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10765652
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: September 8, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Marco Fazzari, Bruce A. Freeman, Francisco Jose Schopfer
  • Patent number: 10765653
    Abstract: The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: September 8, 2020
    Assignee: Children's Hospital & Research Center Oakland
    Inventor: Claudia R. Morris
  • Patent number: 10765654
    Abstract: The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 8, 2020
    Assignee: University of Vermont and State Agricultural College
    Inventor: Diane M. Jaworski
  • Patent number: 10765655
    Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-?, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: September 8, 2020
    Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of BioScience and Biotechnology
    Inventors: Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Ok-Kyoung Kwon, Seung Hyung Kim, Chan Mi Chun, Tae-Suk Lee, Yong-Hae Han, Ki Young Sohn, JongKoo Kang, Hye Kyung Kim
  • Patent number: 10765656
    Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: September 8, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10765657
    Abstract: The invention describes a method for treating a parasitic infection or infestation, particularly sea lice, in a fish by administering an effective amount of selamectin.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: September 8, 2020
    Assignee: Zoetis Services LLC
    Inventors: John Adam Wendt, David Jose Asper, Stacy Ross
  • Patent number: 10765658
    Abstract: Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: September 8, 2020
    Assignee: Mastix LLC
    Inventors: Robert Estey, William O. Brisben
  • Patent number: 10765659
    Abstract: The invention relates to enhanced tulathromycin for use in the treatment, metaphylaxis or prevention of a microbial infection, characterized in that a compound of formula (I) is used in combination with tulathromycin at a weight ratio compound of formula (I):microbial agent of 8:1 to 1:10, and in that the microbial infection is induced in particular by a strain A pathogen in which the concentration of compound (I) satisfies the following equation: [C]<[MIC]/x, where [C] is the concentration according to the invention of compound (I) to be used in strain A, [MIC] is the minimum inhibitory concentration measured for compound (I) alone in strain A, and x is at least 100, advantageously at least 1000, more advantageously between 2000 and 10,000, or even greater than 50,000.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: September 8, 2020
    Assignee: SEPTEOS
    Inventor: Nicolas Tesse
  • Patent number: 10765660
    Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 8, 2020
    Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
  • Patent number: 10765661
    Abstract: The invention provides a method for improving growth performance animals. In particularly, the inventors of the invention found that the addition of a proteolytic enzyme (protease) to regular animal diets results in a significant improvement of growth performance if the proteolytic enzyme is supplemented and combined with vitamin C.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 8, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Aaron Cowieson, Inge Knap
  • Patent number: 10765662
    Abstract: The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: September 8, 2020
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10765663
    Abstract: The present invention provides a food intake regulating agent which improves anorexia and overeating and is safe for ingestion for a long term. The present invention relates to a food intake regulating agent containing 3 kinds of amino acids: threonine, methionine and tryptophan, as active ingredients.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: September 8, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Mika Hamada, Kenji Nagao, Asuka Seki
  • Patent number: 10765664
    Abstract: Disclosed herein are methods for treating or preventing a disease comprising administering a pharmaceutical composition comprising a therapeutically-effective amount of nitazoxanide to a subject having the disease, wherein the disease is causally linked to infection by one or more pathogens selected from the group consisting of members of the genus Ebolavirus, members of the genus Marburgvirus, members of the species dengue virus, human immunodeficiency viruses 1 and 2, and members of the species Mycobacterium tuberculosis.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: September 8, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Anne Goldfeld, Luke Jasenosky, Viraga Haridas, Shahin Ranjbar
  • Patent number: 10765665
    Abstract: A formulation, especially one that is topically administered, comprising a combination of rapamcycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat any disease associated with inflammation and/or any inflammatory skin disease.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: September 8, 2020
    Inventor: Jeffrey Melin
  • Patent number: 10765666
    Abstract: Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Treatment of tics using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Treatment of stuttering using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Therapeutic compositions that may be used to improve one or more symptoms of Tourette syndrome are provided. Therapeutic compositions that may be used to improve one or more symptoms of tics are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of stuttering.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: September 8, 2020
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Patent number: 10765667
    Abstract: The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: September 8, 2020
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: William Forbes, Enoch Bortey
  • Patent number: 10765668
    Abstract: The present invention relates to: an oral tablet composition comprising amorphous dexlansoprazole, mannitol having an average particle size of 100 to 400 ?m, a disintegrating agent and a lubricant; an oral tablet comprising same; and a method for manufacturing same. The oral tablet composition, according to the present invention, exhibits excellent hardness, has a shortened disintegration time, and at the same time, may be used to provide an oral tablet having improved friability. In addition, according to the present invention, a dry direct compression method is used as the method for manufacturing the oral tablet, and thus an increase in production efficiency by simplifying the production process may be achieved.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: September 8, 2020
    Assignee: LOTTE FINE CHEMICAL CO., LTD.
    Inventors: Kwang Il Shin, Kyung Yeol Park, Sang Youb Lee
  • Patent number: 10765669
    Abstract: The present invention relates to a pharmaceutical composition the prevention or treatment of DYRK-related diseases containing a pyridine-based compound as an active ingredient, a pyridine-based compound of the present invention which is used as an active ingredient of the pharmaceutical composition inhibits the activity of DYRK1A with very high efficacy and selectivity, thereby can be used effectively in the prevention or treatment of DYRK-related diseases, such as Down syndrome, degenerative brain diseases, cancer, and metabolic diseases.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: September 8, 2020
    Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sungchan Cho, Miri Choi, Joo Youn Lee
  • Patent number: 10765670
    Abstract: This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 8, 2020
    Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Franck Mouthon, Mathieu Charveriat
  • Patent number: 10765671
    Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: September 8, 2020
    Assignee: NORTIC HOLDINGS INC.
    Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
  • Patent number: 10765672
    Abstract: The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: September 8, 2020
    Assignee: FibroGen, Inc.
    Inventors: David Conca, Lee Allen Flippin, Scott David Leigh, Claudia Witschi, Lee Robert Wright
  • Patent number: 10765673
    Abstract: The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 8, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventors: Michael H. Cardone, David J. Richard
  • Patent number: 10765674
    Abstract: This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: September 8, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Lieven Elvire Colette Baert, Paulus Joannes Lewi, Jan Heeres
  • Patent number: 10765675
    Abstract: A method for treating a sarcoma by administering a tyrosine kinase inhibitor and a biguanide compound. Also described is a method for treating a tumor of the Ewing Sarcoma family by obtaining a tumor sample; determining in the sample gene expression levels of ACTB, B2M, MLH1, PRKDC, XPC, APEX1, ERCC5, MMS19, or RAD23; and administering a tyrosine kinase inhibitor and a biguanide compound. Furthermore, a pharmaceutical composition for treating a Ewing family tumor is disclosed. The composition contains a tyrosine kinase inhibitor, a biguanide compound, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: September 8, 2020
    Assignee: The Methodist Hospital
    Inventors: Hong Zhao, Stephen T. C. Wong
  • Patent number: 10765676
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: September 8, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura